U.S. markets closed

Medical Marijuana, Inc. (MJNA)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.0487-0.0078 (-13.81%)
At close: 3:59PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.0565
Open0.0590
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0460 - 0.0590
52 Week Range0.0100 - 0.2200
Volume65,886,535
Avg. Volume62,190,930
Market Cap48.689M
Beta (5Y Monthly)0.15
PE Ratio (TTM)24.35
EPS (TTM)0.0020
Earnings DateNov 17, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Medical Marijuana, Inc. Subsidiary Kannaway® Announces February 2021 as the Best Month in Company History for Japan Division
    GlobeNewswire

    Medical Marijuana, Inc. Subsidiary Kannaway® Announces February 2021 as the Best Month in Company History for Japan Division

    SAN DIEGO, CA, March 03, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Medical Marijuana, Inc. (OTC: MJNA) (the “Company”), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands and supply chain, announced today that the Japanese division of its subsidiary Kannaway® had its best sales month ever in Company history in February 2021. “When we first entered the Japanese market in late 2019, we were one of the first companies offering cannabidiol (CBD) products in the country and saw a great opportunity to give consumers the high-quality products they had been asking for,” said Kannaway® CEO Blake Schroeder. “Since then, our team has done tremendous work expanding our reach and footprint in Japan.” The Japanese CBD market looks to continue rapidly expanding in the coming years. According to Research and Markets, the global CBD oil market is expected to reach $5.3 billion by 2025 with Asia-Pacific as one of the fastest-growing regions. “While leading our team in Japan, I have seen the positive response to our offerings in the country first-hand. Our team has shown what can be done with hard work and a distinguishing product offering and I look forward to our further growth,” said Kannaway® Japan Division General Manager Peter Dale. To learn more about Kannaway®, please visit the Company online at https://www.kannaway.com/. About Kannaway® Kannaway® is a network sales and marketing company specializing in the sales and marketing of hemp-based botanical products. Kannaway® currently hosts weekly online sales meetings and conferences across the United States, offering unique insight and opportunity to sales professionals who are desirous of becoming successful leaders in the sale and marketing of hemp-based botanical products. About Medical Marijuana, Inc. We are a company of firsts®. Medical Marijuana, Inc. (MJNA) is a cannabis company with three distinct business units in the non-psychoactive cannabinoid space: a global portfolio of cannabinoid-based nutraceutical brands led by Kannaway® and HempMeds®; a pioneer in sourcing the highest-quality legal non-psychoactive cannabis products derived from industrial hemp; and a cannabinoid-based clinical research and botanical drug development sector led by its pharmaceutical investment companies and partners including AXIM® Biotechnologies, Inc. and Neuropathix, Inc. Medical Marijuana, Inc. was named a top CBD producer by CNBC. Medical Marijuana, Inc. was also the first company to receive historic import permits for CBD products from the governments of Brazil, Mexico, Argentina, and Paraguay and is a leader in the development of international markets. The company’s flagship product Real Scientific Hemp Oil has been used in several successful clinical studies throughout Mexico and Brazil to understand its safety and efficacy. Medical Marijuana, Inc.’s headquarters is in San Diego, California, and additional information is available at OTCMarkets.com or by visiting www.medicalmarijuanainc.com. To see Medical Marijuana, Inc.’s corporate video, click here. Shareholders and consumers are also encouraged to buy CBD oil and other products at Medical Marijuana, Inc.’s shop. FORWARD-LOOKING DISCLAIMER This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein. FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. LEGAL DISCLOSURE Medical Marijuana, Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act. CONTACT: Public Relations Contact: Kathryn Brown Account Supervisor CMW Media P. 858-264-6600 kathryn@cmwmedia.com www.cmwmedia.com Investor Relations Contact: P. (858) 283-4016 Investors@medicalmarijuanainc.com

  • Medical Marijuana, Inc. Subsidiary Kannaway® Receives BSCG Certified Drug-Free Approval for Its Pure Gold CBD
    GlobeNewswire

    Medical Marijuana, Inc. Subsidiary Kannaway® Receives BSCG Certified Drug-Free Approval for Its Pure Gold CBD

    Pure Gold Recognized as Free of Substances Banned by US Anti-Doping Agency (USADA) and Professional Sports Leagues SAN DIEGO, CA, Feb. 24, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Medical Marijuana, Inc. (OTC: MJNA) (the “Company”), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands and supply chain, announced today that its subsidiary Kannaway® has received Certified Drug Free approval from the Banned Substances Control Group (BSCG), a leading third-party certification and testing provider of dietary supplements and natural products, for its broad-spectrum cannabidiol (CBD) product Pure Gold. “As pioneers in the CBD industry, we were one of the first companies to conduct third-party testing on all of our products and provide those results to our customers,” said Medical Marijuana, Inc. CEO Dr. Stuart Titus. “This certification furthers our dedication to providing athletes and general consumers alike the confidence to enjoy Pure Gold CBD without the fear of drug testing.” BSCG is the standard in testing for third-party certification that ensures products meet quality specifications and are not contaminated with drugs or agents that can lead to health concerns or positive drug tests. The BSCG Certified Drug Free program requires companies to submit their products through a thorough toxicology review, ingredient evaluation, Good Manufacturing Practices (GMP) quality control process review, and continual random product testing. It provides protection against drugs on the World Anti-Doping Agency (WADA) Prohibited List as well as prescription over-the-counter (OTC) and illicit drugs not banned in sports. “The greatest value that we can provide our customers with is trust and we aim to offer this time and time again by guaranteeing that our products are of the highest quality, safe, consistent, and accurately labeled,” said Kannaway® CEO Blake Schroeder. “We take every opportunity we are given to test and certify our products and hope that consumers see that as our commitment to them." To learn more about BSCG or view Kannaway’s certification, please visit https://kannaway.com/news/content/pure-gold-1500-mg-receives-certified-cbd-seal-by-bscg,4,822.html. About Kannaway® Kannaway® is a network sales and marketing company specializing in the sales and marketing of hemp-based botanical products. Kannaway® currently hosts weekly online sales meetings and conferences across the United States, offering unique insight and opportunity to sales professionals who are desirous of becoming successful leaders in the sale and marketing of hemp-based botanical products. About Medical Marijuana, Inc. We are a company of firsts®. Medical Marijuana, Inc. (MJNA) is a cannabis company with three distinct business units in the non-psychoactive cannabinoid space: a global portfolio of cannabinoid-based nutraceutical brands led by Kannaway® and HempMeds®; a pioneer in sourcing the highest-quality legal non-psychoactive cannabis products derived from industrial hemp; and a cannabinoid-based clinical research and botanical drug development sector led by its pharmaceutical investment companies and partners including AXIM® Biotechnologies, Inc. and Neuropathix, Inc. Medical Marijuana, Inc. was named a top CBD producer by CNBC. Medical Marijuana, Inc. was also the first company to receive historic import permits for CBD products from the governments of Brazil, Mexico, Argentina, and Paraguay and is a leader in the development of international markets. The company’s flagship product Real Scientific Hemp Oil has been used in several successful clinical studies throughout Mexico and Brazil to understand its safety and efficacy. Medical Marijuana, Inc.’s headquarters is in San Diego, California, and additional information is available at OTCMarkets.com or by visiting www.medicalmarijuanainc.com. To see Medical Marijuana, Inc.’s corporate video, click here. Shareholders and consumers are also encouraged to buy CBD oil and other products at Medical Marijuana, Inc.’s shop. FORWARD-LOOKING DISCLAIMER This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein. FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. LEGAL DISCLOSURE Medical Marijuana, Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act. CONTACT: Public Relations Contact: Kathryn Brown Account Supervisor CMW Media P. 858-264-6600 kathryn@cmwmedia.com www.cmwmedia.com Investor Relations Contact: P. (858) 283-4016 Investors@medicalmarijuanainc.com

  • Medical Marijuana, Inc. Subsidiary Kannaway® Submits Novel Foods Application for CBD Products Through European Industrial Hemp Association Consortium
    GlobeNewswire

    Medical Marijuana, Inc. Subsidiary Kannaway® Submits Novel Foods Application for CBD Products Through European Industrial Hemp Association Consortium

    SAN DIEGO, CA, Feb. 22, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Medical Marijuana, Inc. (OTC: MJNA) (the “Company”), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands and supply chain, announced today that its subsidiary Kannaway® has submitted its Novel Foods application for its cannabidiol (CBD) products to the UK’s Food Standards Agency (FSA) through the European Industrial Hemp Association (EIHA) Novel Foods Consortium. “We are witnessing a pivotal moment in history when the global appetite for free access to CBD for all people is very high,” said Medical Marijuana, Inc. CEO Dr. Stuart Titus. “We see this in the US with many recent positive discussions among US congressional officials to pass legislation for federal legalization of cannabis but also new bills for CBD to be regulated as a dietary supplement and food ingredient. In the United Kingdom, there are measures to secure that market’s unity, safety and efficacy for the sale of CBD. With regard to Europe, we could not be more excited to continue the push for free access to all." The EIHA Novel Food Consortium, formed in June 2020, allows Kannaway® to strengthen its commitment to provide free access to CBD-based products throughout the EU. Now that the application has been submitted to the FSA, the next step is to undertake the submission to the European Food Safety Authority (EFSA). “It is very encouraging to see the industry’s leading companies banding together to ensure free access,” said Kannaway® Managing Director of International Janne Heimonen. “We appreciate the EIHA and its other members for their unified efforts to bear the costs for the necessary toxicological studies and additional approval procedures.” About Kannaway® Kannaway® is a network sales and marketing company specializing in the sales and marketing of hemp-based botanical products. Kannaway® currently hosts weekly online sales meetings and conferences across the United States, offering unique insight and opportunity to sales professionals who are desirous of becoming successful leaders in the sale and marketing of hemp-based botanical products. About Medical Marijuana, Inc. We are a company of firsts®. Medical Marijuana, Inc. (MJNA) is a cannabis company with three distinct business units in the non-psychoactive cannabinoid space: a global portfolio of cannabinoid-based nutraceutical brands led by Kannaway® and HempMeds®; a pioneer in sourcing the highest-quality legal non-psychoactive cannabis products derived from industrial hemp; and a cannabinoid-based clinical research and botanical drug development sector led by its pharmaceutical investment companies and partners including AXIM® Biotechnologies, Inc. and Neuropathix, Inc. Medical Marijuana, Inc. was named a top CBD producer by CNBC. Medical Marijuana, Inc. was also the first company to receive historic import permits for CBD products from the governments of Brazil, Mexico, Argentina, and Paraguay and is a leader in the development of international markets. The company’s flagship product Real Scientific Hemp Oil has been used in several successful clinical studies throughout Mexico and Brazil to understand its safety and efficacy. Medical Marijuana, Inc.’s headquarters is in San Diego, California, and additional information is available at OTCMarkets.com or by visiting www.medicalmarijuanainc.com. To see Medical Marijuana, Inc.’s corporate video, click here. Shareholders and consumers are also encouraged to buy CBD oil and other products at Medical Marijuana, Inc.’s shop. FORWARD-LOOKING DISCLAIMER This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein. FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. LEGAL DISCLOSURE Medical Marijuana, Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act. CONTACT: Public Relations Contact:Kathryn BrownAccount SupervisorCMW MediaP. 858-264-6600kathryn@cmwmedia.comwww.cmwmedia.com Investor Relations Contact:P. (858) 283-4016Investors@medicalmarijuanainc.com